Clinvest - Active Studies

Active Studies

We are constantly seeking participants for a number of studies. Please apply to any studies for which you may qualify, or call us at (417) 883-7889 for more information!

Psoriatic Arthritis

Abbvie M15-572


The study is for subjects 18 and older. The study duration is up to 3 years. Subject will receive both oral study drug once daily and subcutaneous study drug every other week. Period 1 is 56 weeks and 13 site visits. Subject will have a site visit at week 56 and every 12 weeks thereafter.

Psoriatic Arthritis

Abbvie M15-572


The study is for subjects 18 and older. The study duration is up to 3 years. Subject will receive both oral study drug once daily and subcutaneous study drug every other week. Period 1 is 56 weeks and 13 site visits. Subject will have a site visit at week 56 and every 12 weeks thereafter.

APPLY NOW

Psoriatic Arthritis

Abbvie M15-554


The research study is available for participants 18 and older. The subject will take the study drug once daily. There are 13 office visits in Period 1. The study duration is up to 3 years. Subject will have a study visit at week 56 and every 12 weeks thereafter.

Psoriatic Arthritis

Abbvie M15-554


The research study is available for participants 18 and older. The subject will take the study drug once daily. There are 13 office visits in Period 1. The study duration is up to 3 years. Subject will have a study visit at week 56 and every 12 weeks thereafter.

APPLY NOW

Rheumatoid Arthritis Prevention

Abbvie M15-925

Clinvest Research is currently enrolling participants for a phase 3 clinical study investigating a new selective JAK1 inhibitor for Rheumatoid Arthritis. Participants need to be over 18 years of age, have diagnosis of Rheumatoid Arthritis, have had an inadequate response or intolerant to previous treatments, and on a stable dose of a Synthetic Disease Modifying Anti-Rheumatic Drug. The study is up to 5 years in duration. Compensation for time and travel may be provided and study related care is at no cost.

Rheumatoid Arthritis Prevention

Abbvie M15-925

Clinvest Research is currently enrolling participants for a phase 3 clinical study investigating a new selective JAK1 inhibitor for Rheumatoid Arthritis. Participants need to be over 18 years of age, have diagnosis of Rheumatoid Arthritis, have had an inadequate response or intolerant to previous treatments, and on a stable dose of a Synthetic Disease Modifying Anti-Rheumatic Drug. The study is up to 5 years in duration. Compensation for time and travel may be provided and study related care is at no cost.

APPLY NOW

Chronic Migraine Prevention

Alder ALD403-CLIN-011

A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel 20 Week Study of the Efficacy and Safety of the Tx360® Nasal Applicator for Transnasal Sphenopalatine Ganglion Block in the Treatment of Chronic Migraine.

Chronic Migraine Prevention

Alder ALD403-CLIN-011

A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel 20 Week Study of the Efficacy and Safety of the Tx360® Nasal Applicator for Transnasal Sphenopalatine Ganglion Block in the Treatment of Chronic Migraine.

APPLY NOW